• Released during Liver Health Awareness Month and based primarily on market research of healthcare professionals, Salix Pharmaceuticals’ Annual Liver Health Trends Report reveals that more than a third of gastro- enterologists surveyed noted an increase in patient hospitalizations due to cirrhosis over the past year

  • The report indicates that repayment difficulties negatively affect the management of chronic liver disease, as reported by survey respondents

LAVAL, QC, October 12, 2022 /PRNewswire/ — Salix Pharmaceuticals (“Salix”), the gastroenterology business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today released the Salix Liver Health Trends Annual Report, Second Edition with the latest chronic liver disease (CLD) care information and findings that include a continued increase in hospitalizations and mortality from CLD and cirrhosis, as well as gaps in care and knowledge that can prevent early diagnosis and optimal management of CLD, cirrhosis and its complications.

The trends report, which is based on a survey of 400 healthcare providers (HCPs) who treat patients with CLD, qualitative interviews with HCPs and secondary research from peer-reviewed publications, reveals gaps in adoption of national treatment guidelines, particularly among primary care physicians (PCPs). Perceived issues with payer coverage (due to complexity/prior authorization rejections) and high out-of-pocket costs/inability to pay for treatment were found to be major factors negatively impacting initiation treatment or causing treatment interruptions.

“Salix is ​​committed to providing resources that inform, educate and help healthcare providers improve care for people living with chronic liver disease, cirrhosis and complications such as hepatic encephalopathy,” said Nicolas Kayel, Vice President, IG Marketing, Salix. “This year’s report indicates a continued rise in mortality from chronic liver disease and cirrhosis, now surpassing diabetes or stroke among 25-54 year olds1. It is clear from patient and provider research that there is a real need for more education and engagement resources to support the management of LDC. It is our hope the Salix Liver Health Trends Annual Report will increase awareness of this growing public health problem, help fill knowledge gaps, and provide tools for healthcare providers that can improve disease identification and management.

The Salix Liver Health Annual Trends Report is released in October during Liver Health Awareness Month as part of an effort to provide healthcare providers with the most up-to-date information about liver disease.

“The Global Liver Institute applauds the release of this year’s report Liver Health Trends Annual Report which will help to better understand the personal and societal impact of chronic liver disease and potentially help to address its underdiagnosis and undertreatment among the approximately 4.5 million adults in the United States living with chronic liver disease. sickness2,” said Donna R. CryerJD, Founder and CEO, Global Liver Institute.

Complete Salix Discoveries Liver Health Trends Annual Report as well as resources for healthcare providers to help identify and manage patients with CLD and cirrhosis can be found at

Some findings of the report include:

  • 34% of gastroenterologists surveyed say they have seen an increase in patient hospitalizations due to alcoholic cirrhosis of the liver in the past year

  • 38% of respondents did not know and/or could not name the national guidelines for the management of CLD

  • 55% of PCPs and 49% of nurse practitioners/physician assistants surveyed are not comfortable treating overt hepatic encephalopathy (OHE) and seek a consultation

  • 50% of providers surveyed say a patient’s ability to pay for out-of-pocket expenses is very or extremely important to patient outcomes with LDC

About the Liver Health Annual Trends Report Methodology
The Liver Health Trends Annual Report on chronic liver disease (CLD) includes information gathered from an online survey, qualitative telephone interviews, and secondary research from peer-reviewed publications. An independent recruiting firm invited over 400 health care providers to participate in this research project during May 2022. Provider participation (N=400) in the survey required individuals to be active in clinical practice and treat more than 4 CPD patients per year and consisted of the following subgroups: 100 community gastroenterologists, 100 residential specialists, 100 primary care physicians (PCPs) and 100 nurse practitioners/physician assistants (NP/PAs). In addition to completing the online survey, 15 physicians and 5 NP/PAs also completed in-depth telephone interviews (Table 1). Quotes from in-depth interviews throughout this report represent the opinions of these respondents. For the online survey, data analysis was performed using QPSMR data analysis software.

The report strives to be representative of the lived experience of all segments of physicians and the diversity that exists within United States regarding patient management and the economic and social factors that influence the management of patients with CPD. Due to the limitations of this report, not all results can be generalized to all CLD providers and patient populations. Furthermore, this report does not contain all the questions posed in the survey and in-depth interviews.

Secondary search of peer-reviewed publications
Secondary research was conducted using Google and PubMed searches to identify relevant peer-reviewed publications and sources as noted in the report. In addition, data on treatment usage and claims are sourced from IQVIA. Secondary research may not reflect all published data. A systematic review was not performed. Although the included publications are peer-reviewed, this secondary research as a whole was not.

To raise awareness and awareness of CLD and SE, Salix also offers other online resources, including:

  • Provides patients/caregivers with information and resources on SE on how to work with their healthcare provider to help manage the condition, a complication of cirrhosis

  • Provides health care providers with information on unseen aspects and considerations in caring for patients with HE

About Salix

Salix Pharmaceuticals is one of the world’s largest specialty pharmaceutical companies committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and commercialized innovative products to improve the lives of patients and arm healthcare providers with life-changing solutions for many chronic and debilitating diseases. Salix currently markets its product line to US healthcare providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is ​​headquartered in Bridgewater, New Jersey. For more information about Salix, visit and connect with us at Twitter and LinkedIn.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a diversified global pharmaceutical company whose mission is to improve people’s lives through our healthcare products. We develop, manufacture and market a range of products primarily in the areas of gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. With our leading sustainable brands, we deliver on our commitments by building an innovative company dedicated to advancing global health.

Forward-looking statements

This press release may contain forward-looking statements about the future performance of the Company, which can generally be identified by the use of the words “anticipates”, “hopes”, “expects”, “intends”. , “expects”, “should”, “could”, “will”, “may”, “believes”, “subject to” and variations or similar expressions. These statements are based on management’s current expectations and beliefs. and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to the overall business of company, including those more fully described in the company’s most recent Annual Report on Form 10-K and detailed from time to time in the company’s other filings with U.S. Securities and Exc hange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.

©2022 Salix Pharmaceuticals or its affiliates.

1 Xu JQ, Murphy SL, Kochanek KD, Arias E. Deaths: Final data for 2019. Natl Vital Stat Rep. 70(8). Hyattsville, MD: National Center for Health Statistics. 2021.
2 Centers for Control and Prevention of Disasters. Chronic liver disease and cirrhosis. Accessed September 9, 2022.

Gianna Scalera
[email protected]
(908) 541-2110



View original content to download multimedia: growing -chronic-liver-disease-and-cirrhotic-patient-population-301646728.html

SOURCE Bausch Health Companies Inc.

Comments are closed.